Table 3.

Hazard ratios of incident psoriasis and PsA according to hypercholesterolemia with and without related medication use

	Cases	Person- Yearsa	Age-adjusted HR (95% CI)	Multivariate- adjusted HRb (95% CI)	Multivariate- adjusted HRc (95% CI)
Psoriasis
No hypercholesterolemia	427	1,006,906	1.00	1.00	1.00
Hypercholesterolemia with no medication	180	276,817	1.45 (1.21, 1.73)	1.28 (1.07, 1.53)	1.26 (1.05, 1.51)
Hypercholesterolemia with regular statins use	36	34,805	1.75 (1.22, 2.50)	1.36 (0.95, 1.95)	1.21 (0.83, 1.76)
Hypercholesterolemia with regular other cholesterol-lowering drugs use	7	4,361	2.62 (1.23, 5.57)	2.05 (0.96, 4.38)	1.78 (0.83, 3.83)
Psoriasis with concomitant PsA
No hypercholesterolemia	93	1,002,575	1.00	1.00	1.00
Hypercholesterolemia with no medication	60	275,541	2.11 (1.52, 2.95)	1.64 (1.17, 2.29)	1.62 (1.15, 2.27)
Hypercholesterolemia with regular statins use	11	34,687	2.22 (1.15, 4.30)	1.40 (0.72, 2.72)	1.23 (0.62, 2.44)
Hypercholesterolemia with regular other cholesterol-lowering drugs use	2	4,351	3.21 (0.78, 13.2)	1.94 (0.47, 8.03)	1.65 (0.39, 6.95)

^aPerson-years of hypercholesterolemia with no medication, statins use, and other cholesterol-lowering drugs use did not add up to total hypercholesterolemia person-years because a small proportion of participants used statins and other drugs simultaneously.

^bSimultaneously adjusted for age, BMI (<24.9, 25–29.9, 30–34.9, and ≥35 kg/m²), alcohol intake (no, <5.0, 5.0–9.9 or ≥10.0 g/d), physical activity (<3.0, 3.0–8.9, 9.0–17.9, 18.0–26.9 or ≥27.0 metabolic equivalent hours/week), and smoking status (never, past, current smoking with 1–14, 15–24, or ≥25 cigarettes/day).

^cAdditionally adjusted for cardiovascular disease (yes or no), type 2 diabetes (yes or no), and hypertension (yes or no).